Miltefosine
C21H46NO4P — CID 3599
View drug profile → miltefosineData last refreshed: (MolForge compound catalog, from PubChem)
About Miltefosine
Miltefosine (PubChem CID 3599) has the molecular formula C21H46NO4P and a molecular weight of 407.58 g/mol. Its IUPAC name is hexadecyl 2-(trimethylazaniumyl)ethyl phosphate.
Molecular Properties
| Compound Name | Miltefosine |
|---|---|
| PubChem CID | 3599 |
| Molecular Formula | C21H46NO4P |
| Molecular Weight | 407.58 g/mol |
| Exact Mass | 407.32 |
| IUPAC Name | hexadecyl 2-(trimethylazaniumyl)ethyl phosphate |
| SMILES | CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C |
| InChI | InChI=1S/C21H46NO4P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-25-27(23,24)26-21-19-22(2,3)4/h5-21H2,1-4H3 |
| InChIKey | PQLXHQMOHUQAKB-UHFFFAOYSA-N |
| XLogP | 5.68 |
| TPSA | 58.59 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 20 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 407.58 |
| LogP ≤ 5 | 5.68 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Aliphatic_long_chain', 'substructure': 'N/A'}, {'alert_name': 'phosphor', 'substructure': 'N/A'}, {'alert_name': 'quaternary_nitrogen_2', 'substructure': 'N/A'} |
|---|
Related Compounds
🔗 Related compound forms
Tautomers, salt forms, and related identifiers from PubChem CID-Parent + CID-Component (110 M edges in our graph).
Parent compound (canonical tautomer)
Salt forms / components
Frequently Asked Questions
Browse: Molecules: M · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 3599 — identifiers, structure, computed properties (public domain)
- DrugCentral drug card 1810 — approved-drug record (CC BY-SA 4.0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.